Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol

Current Medical Research and Opinion

Volumn 25, Issue 6, 2009, Pages 1355-1363

  Toth, Peter P ^a,b,c   Zarotsky, Victoria ^d   Sullivan, Jane M ^d   Laitinen, Dave ^e  

^a Sterling Rock Falls Clinic ^*  (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

^c SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d i3 Innovus   (United States)

^e ABBOTT LABORATORIES   (United States)

Author keywords

Anticholesteremic agents; Cholesterol; Coronary disease; Dyslipidemias; HDL; Niacin; Treatment outcome; Triglycerides

Indexed keywords

AMLODIPINE PLUS ATORVASTATIN; ATORVASTATIN; CERIVASTATIN; CLOFIBRATE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL PRACTICE; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; TREATMENT OUTCOME;

ADULT; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CLOFIBRIC ACID; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOALPHALIPOPROTEINEMIAS; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; NIACIN; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TRIGLYCERIDES;

EID: 67649422332     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902910450     Document Type: Article

References (39)

1. Davidson MH, Toth PP. High-density lipoprotein metabolism: potential therapeutic targets. Am J Cardiol 2007;100:n32-40
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421
3. Thom T, Haase N, Rosamond W, et al. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006;113:e85-151
4. Gaw A. Evidence based approach for the management of mixed hyperlipidaemia. Atherosclerosis 1998;137(Suppl):S97-100 (Pubitemid 28294214)
5. Birjmohun RS, van der Steeg WA, Stroes ESG, et al. The role of the high-density lipoprotein (HDL) particle in atherogenesis and potential methods to increase HDL concentrations. Ned Tijdschr Geneeskd 2006;150:2245-2250 (Pubitemid 44621983)
6. Toth PP. When high is low: approaches to raising low high-density lipoprotein cholesterol levels. Curr Cardiol Rep 2008;10:488-496
7. Ashen MD, Blumenthal RS. Low HDL cholesterol levels. N Engl J Med 2005;353:1252-1260 (Pubitemid 41345947)
8. Rizos E, Mikhalidis DP. Are high-density lipoprotein and triglyceride levels important in secondary prevention? Impressions from the BIP and VA-HIT trials. Int J Cardiol 2002;82:199-207 (Pubitemid 34241573)
9. Miller M, Ginsberg HN, Schaefer EJ. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol 2008;101:1003-1008
10. Gordon D, Probstfield J, Garrison R, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15 (Pubitemid 19043669)
11. BIP InvestigatorsSecondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-27 (Pubitemid 30430548)
12. Goldenberg I, Goldbourt U, Boyko V, et al.; BIP Study Group. Relation between on-treatment increments in serum high density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial). Am J Cardiol 2006;97:466-471 (Pubitemid 43190032)
13. American Diabetes Association. Standards in medical care in diabetes - 2006 (Position Statement). Diabetes Care 2006;29:4-42
14. Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in metabolic syndrome: a randomized trial. JAMA 2004;292:1440-1446 (Pubitemid 39258336)
15. Toth PP. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am J Cardiol 2005;96:50-8K
16. Tenenbaum A, Fisman E, Motro M, et al. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 2006;5:20 (Pubitemid 44524381)
17. Fazio S. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy. Clin Ther 2008;30:294-306
18. Vittone F, Chait A, Morse JS, et al. Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: a subgroup analysis of the HDL-Atherosclerosis Treatment Study (HATS). J Clin Lipidol 2007;1:203-210 (Pubitemid 47055291)
19. Assmann G, Schulte H, Funke H, et al. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J 1998;19:8-14 (Pubitemid 28470458)
20. Grundy SM. Consensus statement: role of therapy with 'statins' in patients with hypertriglyceridemia. Am J Cardiol 1998;81:1B-6B
21. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-219 (Pubitemid 26266496)
22. Goldberg AC. Combination therapy of dyslipidemia. Curr Treat Options Cardiovasc Med 2007;9:249-258 (Pubitemid 47181091)
23. Parhofer KG. Beyond LDL-cholesterol: HDL-cholesterol as a target for atheroscleross prevention. Exp Clin Endocrinol Diabetes 2005;113:414-417
24. Bersot T, Haffner S, Harris WS, et al. Hypertriglyceridemia: management of atherogenic dyslipidemia. J Fam Pract 2006;55:S1-8
25. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308 (Pubitemid 47080484)
26. Castelli WP, Anderson K, Wilson PW, et al. Lipids and risk of coronary heart disease. The Framingham Study. Ann Epidemiol 1992;2:23-28
27. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-458
28. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-219 (Pubitemid 26266496)
29. La Rosa JC. Triglycerides and coronary risk in women and the elderly. Arch Intern Med 1997;157:961-968 (Pubitemid 27190883)
30. Wascher TC. The era of statins - is there still a place for other classes of lipid-lowering drugs? Heart Drug 2005;5:34-38
31. Robins SJ, Collins D, Wittes JT, et al.; VA-HIT Study Group. Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-1591
32. Miller M, Cannon CP, Murphy SA, et al.; PROVE IT-TIMI 22 investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2008;51:724-730 (Pubitemid 351221217)
33. Klingman D, Williams SA, Benner JS, et al. Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey. Am Heart J 2005;150:595-601
34. Davidson MH. Differences between clinical trial efficacy and real-world effectiveness. Am J Manag Care 2006;12:S405-11 (Pubitemid 44865051)
35. Goebel LJ, Bailony F, Khattak AJ, et al. Physician and patient barriers to adherence with cholesterol guidelines. W V Med J 2006;102:23-26
36. Toth PP, Harper CR, Jacobson TA. Clinical characterization and molecular mechanisms of statin myopathy. Expert Rev Carodiovasc Ther 2008;6:955-969
37. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil+any statin. Am J Cardiol 2005;95:120-122 (Pubitemid 40051126)
38. Stacy TA, Egger A. Results of retrospective chart review to determine improvement in lipid goal attainment in patients treated by high-volume prescribers of lipid-modifying drugs. J. Manag Care Pharm 2006;12:745-751 (Pubitemid 47394435)
39. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497